Mr. Hugh MacNaught reports

VENTRIPOINT DIAGNOSTICS ANNOUNCES CANCELLATION AND RE-GRANT OF OPTIONS, GRANT OF ANNUAL INCENTIVE OPTIONS AND PRIVATE PLACEMENT

Ventripoint Diagnostics Ltd. incorrectly granted 7,246,250 stock options of the company to various officers, employees and consultants of the company during the period of Feb. 27, 2025, to May 27, 2026, as the company did not obtain the necessary annual shareholder approval for the company's stock option plan. The company had previously cancelled 250,000 option grants, which will not be regranted, and effective June 30, 2026, has cancelled 4,301,250 option grants, which included one million options granted to an officer of the company. The company has regranted 3,151,250 of the cancelled options, including one million to an officer of the company, and granted 3,241,500 annual incentive option grants to directors, officers, employees and consultants of the company, which included 1.5 million to officers and directors, at the current market price on July 8, 2026, under the stock option plan, which was approved at the company's recent shareholder meeting on May 27, 2026. A total of 6,392,750 were granted at an exercise price of 9.5 cents for terms of two to 10 years and vesting immediately to over three years. The company has 13.7 million options issued at a volume-weighted average exercise price of 16 cents and 5.0 million options available for future grants.

The company also announces that the grant and exercise of an aggregate of 2,695,000 stock options to various employees and consultants of the company will be treated as a non-brokered private placement at prices ranging from 10 cents to 12 cents, with an effective closing date of July 29, 2026, subject to TSX Venture Exchange acceptance.

Out of two million options granted on June 2, 2025, 1.19 million options were exercised at a price of 10 cents and will be included in the private placement.

Out of 1.37 million options granted on June 12, 2025, 900,000 options were exercised at a price of 11 cents and will be included in the private placement.

Out of 2,585,000 options granted on Oct. 14, 2025, 380,000 options were exercised at a price of 11 cents and will be included in the private placement.

Out of 291,250 options granted on Dec. 30, 2025, 225,000 options were exercised at a price of 12 cents and will be included in the private placement.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.